Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel
Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Arcellx Inc. (NASDAQ: ACLX) for USD 115.00...
Arcellx
Gilead’s Kite Expands Partnership with Arcellx for Innovative Cell Therapies
Gilead (NASDAQ: GILD), a leading biopharmaceutical company, has announced an expansion of its 2022 partnership...